Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of Florida
Eli Lilly and Company
Milton S. Hershey Medical Center
Children's Oncology Group
Princess Maxima Center for Pediatric Oncology
St. Jude Children's Research Hospital
USWM, LLC (dba US WorldMeds)
Sun Yat-sen University
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche
Hadassah Medical Organization
Clarity Pharmaceuticals Ltd
Baylor College of Medicine
Memorial Sloan Kettering Cancer Center
Nationwide Children's Hospital
Children's Hospital of Philadelphia
Siriraj Hospital
Bambino Gesù Hospital and Research Institute
Hoffmann-La Roche
Milton S. Hershey Medical Center
University Hospital, Basel, Switzerland
Bayer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Y-mAbs Therapeutics
Bristol-Myers Squibb
Nova Laboratories Limited
Cancer Research UK
Shenzhen Geno-Immune Medical Institute
St. Anna Kinderkrebsforschung
Children's Oncology Group
Celgene
University of California, San Francisco
New Approaches to Neuroblastoma Therapy Consortium
Columbia University
National Institutes of Health Clinical Center (CC)
National University Hospital, Singapore
Sanofi
United Therapeutics
Hadassah Medical Organization
Duke University
Duke University
University of Kentucky
Tehran University of Medical Sciences
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital